$RTX

DA Davidson Adjusts Price Target on RTX to $201 From $219, Maintains Neutral Rating

DA Davidson reduced its price target on RTX from $219 to $201, maintaining a neutral rating. The adjustment reflects the firm's updated outlook on the company's performance. Goldman Sachs also adjusted its target, raising it from $206 to $208.

Original reporting
Published Oct 22, 2026, 12:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RTX
Bearish
high confidence
Mentioned
$RTX
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$RTXBearishMed
01

Why it matters

The downgrade may trigger short‑term selling but long‑term fundamentals could remain intact.

02

Market read

Analyst target cut is the primary new information, offering a modest trading signal for RTX.

03

What to watch

Potential upside from upcoming defense contracts not reflected in the target.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

DA Davidson issued a new research note adjusting RTX's valuation based on recent earnings and market conditions.

Company-level read

Ticker impact

$RTXBearishHigh confidence
Context

DA Davidson lowered RTX's price target to $201 from $219, indicating a fresh analyst downgrade.

Expected impact

likely modest downside as investors price in the lower target

Evidence & confidence

Analyst price‑target reductions typically lead to short‑term sell pressure, especially when the cut is sizable (~8%).

Market effects

May weigh on aerospace & defense peers as analysts reassess valuation multiples.

Limited to U.S. markets; no broader regional effect.

Minimal global impact beyond sector.

Counterpoint

If RTX's underlying order backlog remains strong, the target cut could be an overreaction.

Key entities

  • Raytheon Technologies

    U.S. aerospace and defense conglomerate (ticker RTX).

  • DA Davidson

    Equity research provider issuing the price‑target change.

Related articles

$RTXMed

RTX CEO says Pentagon contracts will drive major expansion in missile production

RTX CEO Chris Calio announced $70B in Pentagon contracts for Raytheon, ensuring nearly a decade of demand visibility. The deals involve Tomahawk, AMRAAM, SM-6, and SM-3 IB missiles. RTX plans to increase production 2-4x over 7-10 years, investing in supply chain and equipment. CFO Neil Mitchill expects revenue and profit growth as costs are charged to programs, with full-rate production by 2030. The contracts include safeguards against budgetary changes and order volume shifts.

$LMTHighAI 8/10

Lockheed Martin Rises 9% as Record Backlog Lifts Outlook; RTX Gains 2%, Northrop Grumman Advances 3%

Lockheed Martin (LMT) rose 9% after reporting Q3 results that beat estimates, with revenue up 11% to $20.7B, EPS at $7.97, and a record $292B backlog. The company raised its 2026 outlook, expecting revenue of $80B-$82B and EPS of $30.35-$30.75. RTX (RTX) and Northrop Grumman (NOC) also gained, up 2% and 3% respectively, as defense stocks outperformed the broader market.

$RTXHighAI 9/10

RTX's Booming Defense Segment Lifts All Ships

RTX reported Q3 2026 revenues of $25B, up from $22.5B YoY, with $59B in new awards boosting its backlog to $340B. Defense segment saw significant growth, while Collins Aerospace and Pratt & Whitney also contributed. Adjusted earnings grew by $1B for the quarter and $1.9B YTD. RTX raised full-year guidance, targeting $97-97.5B in revenue and $7.65-7.75 in EPS.

$RTXHighAI 8/10

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq Composite and Russell 2000 led a three-day market rally, with Nasdaq up 2.14% and Russell 2000 up 2.36% for the week. The Dow and S&P 500 also gained over 1.2%. Several companies reported earnings, including RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group (Nasdaq: CME), M/I Homes (NYSE: MHO), and Lockheed Martin (NYSE: LMT). RTX reported $25.0B in Q3 sales and raised its full-year outlook. Abbott posted 14.5% sales growth. CME Group saw record Q3 revenue.